Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD.

Photo by Ricardo Arce / Unsplash

Frontiers in Medicine Published April 14, 2026 Medically reviewed April 25, 2026 Study authors: Weiying Ou, Yaoyao Wang, Chengyu Hou, Shujuan Hou, Yumei Zhou, Ji Wang, Qi Wang DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that single-target IL-5 therapies show limitations; multi-targeted precision therapies are anticipated as a future frontier for eosinophil-associated diseases.

A systematic review was conducted to assess the landscape of therapies targeting eosinophil-associated diseases, which include asthma, chronic obstructive pulmonary disease (COPD), and other eosinophil-associated conditions. The scope of the review encompassed single-target interventions, multi-target combination therapies involving synergistic inhibition of IL-5 with IL-4/IL-13 and IL-33/ST2 pathways, bispecific antibodies, and small-molecule inhibitors. The review did not report specific sample sizes or detailed population demographics, nor did it provide data on primary or secondary outcomes, p-values, or confidence intervals for the specific interventions analyzed.

The evaluation of single-target interventions revealed significant limitations. Specifically, the review noted that these approaches exhibit insufficient responses in certain patients, highlighting a gap in current therapeutic efficacy for a subset of the population. Detailed safety data, including adverse events, serious adverse events, discontinuations, and overall tolerability, were not reported in the available evidence. Consequently, no specific numerical data regarding safety profiles or effect sizes could be extracted from the systematic review.

Key limitations of the current evidence include the inability to draw definitive conclusions regarding the comparative effectiveness of multi-target versus single-target strategies due to the lack of specific outcome data. The review concludes that multi-targeted precision therapies, tailored to individual inflammatory phenotypes, are anticipated to represent a new frontier in the management of eosinophil-associated diseases. However, this statement reflects anticipation rather than established clinical fact based on the provided data. Further research is required to validate these potential advancements and to establish robust safety and efficacy profiles for these emerging therapeutic classes.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

Eosinophil-associated diseases are a group of inflammatory disorders characterized by abnormal eosinophil infiltration, which significantly impacts patients’ quality of life. Interleukin-5 (IL-5), a critical cytokine that regulates eosinophil development, activation, chemotaxis, and survival, plays a central role in the pathogenesis of these diseases. This review systematically examines the molecular structure and signaling pathways of IL-5, its mechanisms of action in asthma and chronic obstructive pulmonary disease (COPD), and the development and clinical applications of monoclonal antibodies (e.g., mepolizumab, benralizumab, reslizumab) and other biologics targeting IL-5. Although IL-5-targeted therapies have yielded significant results, single-target interventions still exhibit limitations, including insufficient responses in certain patients. To address this, we explore the strategy of multi-target combination therapies, such as the synergistic inhibition of IL-5 with the IL-4/IL-13 and IL-33/ST2 pathways. We also discuss the potential of novel therapeutic approaches, including bispecific antibodies and small-molecule inhibitors. Ultimately, multi-targeted precision therapies, tailored to individual inflammatory phenotypes, are anticipated to represent a new frontier in the management of eosinophil-associated diseases.